Immunotherapies in Alzheimer’s disease: Too much, too little, too late or off-target?

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Acta Neuropathologica

• Publication date

  2016-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00401-015-1518-9PMID 26689922
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

  2016cited by this paper
• 2016 Alzheimer's disease facts and figures

  2016cited by this paper
• Safety and pharmacokinetics of bapineuzumab in a single ascending‐dose study in Japanese patients with mild to moderate Alzheimer's disease

  2016cited by this paper
• N-3 polyunsaturated fatty acid and neuroinflammation in aging and Alzheimer's disease

  2015cited by this paper
• TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models

  2015cited by this paper
• Follow‐up evaluation of cognitive function in the randomized Alzheimer's Disease Anti‐inflammatory Prevention Trial and its Follow‐up Study

  2015cited by this paper
• Clearing the way for tau immunotherapy in Alzheimer's disease

  2015cited by this paper
• The Inflammatory Form of Cerebral Amyloid Angiopathy or “Cerebral Amyloid Angiopathy-Related Inflammation” (CAARI)

  2015cited by this paper
• Brain collection, standardized neuropathologic assessment, and comorbidity in Alzheimer's Disease Neuroimaging Initiative 2 participants

  2015cited by this paper
• Learning by failing: ideas and concepts to tackle γ-secretases in Alzheimer's disease and beyond.

  2015cited by this paper
• Neuroinflammation in Alzheimer's disease.

  2015cited by this paper
• Immunity in arterial hypertension: associations or causalities?

  2015influential reference
• CXCR2 is essential for cerebral endothelial activation and leukocyte recruitment during neuroinflammation

  2015cited by this paper
• TREM2 lipid sensing sustains microglia response in an Alzheimer’s disease model

  2015cited by this paper
• Post-mortem analysis of neuroinflammatory changes in human Alzheimer’s disease

  2015cited by this paper
• Immune attack: the role of inflammation in Alzheimer disease

  2015cited by this paper
• Inflammation, immunity, and hypertensive end-organ damage.

  2015cited by this paper
• Signaling in lymphocyte activation.

  2015influential reference
• Age‐dependent impairment of glucose tolerance in the 3xTg‐AD mouse model of Alzheimer's disease

  2015cited by this paper
• Learning by Failing: Ideas and Concepts to Tackle gamma-Secretases in Alzheimer's Disease and Beyond

  2015cited by this paper
• Biogen's aducanumab raises hope that Alzheimer's can be treated at its source.

  2015influential reference
• CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.

  2015cited by this paper
• CCL11 enhances excitotoxic neuronal death by producing reactive oxygen species in microglia

  2015cited by this paper
• Clinical Trials of Intravenous Immunoglobulin for Alzheimer’s Disease

  2014influential reference
• The evolution of preclinical Alzheimer's disease: implications for prevention trials.

  2014influential reference
• Intravenous immunoglobulin reduces tau pathology and preserves neuroplastic gene expression in the 3xTg mouse model of Alzheimer's disease.

  2014cited by this paper
• Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study

  2014cited by this paper
• Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

  2014cited by this paper
• Anti-ApoE Antibody Given after Plaque Onset Decreases Aβ Accumulation and Improves Brain Function in a Mouse Model of Aβ Amyloidosis

  2014cited by this paper
• Pilot and feasibility studies: is there a difference from each other and from a randomised controlled trial?

  2014cited by this paper
• TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis

  2014cited by this paper
• APOε4 is associated with enhanced in vivo innate immune responses in human subjects.

  2014cited by this paper
• an update on

  2014cited by this paper
• Insulin Reverses the High-Fat Diet–Induced Increase in Brain Aβ and Improves Memory in an Animal Model of Alzheimer Disease

  2014cited by this paper
• Physical exercise in MCI elderly promotes reduction of pro-inflammatory cytokines and improvements on cognition and BDNF peripheral levels.

  2014influential reference
• Microglia receptors and their implications in the response to amyloid β for Alzheimer’s disease pathogenesis

  2014influential reference
• Dual destructive and protective roles of adaptive immunity in neurodegenerative disorders

  2014cited by this paper
• Upregulation of TREM2 Ameliorates Neuropathology and Rescues Spatial Cognitive Impairment in a Transgenic Mouse Model of Alzheimer’s Disease

  2014cited by this paper
• IVIg protects the 3xTg-AD mouse model of Alzheimer’s disease from memory deficit and Aβ pathology

  2014influential reference
• Safety and Pharmacology of Ponezumab (PF-04360365) After a Single 10-Minute Intravenous Infusion in Subjects With Mild to Moderate Alzheimer Disease

  2013cited by this paper
• Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial.

  2013cited by this paper
• IVIG immunotherapy protects against synaptic dysfunction in Alzheimer's disease through complement anaphylatoxin C5a-mediated AMPA-CREB-C/EBP signaling pathway.

  2013influential reference
• CCL2 affects β-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer's disease.

  2013cited by this paper
• MER5101, a Novel Aβ1-15:DT Conjugate Vaccine, Generates a Robust Anti-Aβ Antibody Response and Attenuates Aβ Pathology and Cognitive Deficits in APPswe/PS1ΔE9 Transgenic Mice

  2013cited by this paper
• Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease: A Phase I, Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study

  2013cited by this paper
• The ageing haematopoietic stem cell compartment

  2013cited by this paper
• Complement in Immune and Inflammatory Disorders: Therapeutic Interventions

  2013cited by this paper
• A Therapeutic Antibody Targeting Bace1 Inhibits Amyloid-beta Production in Vivo

  2013cited by this paper
• Adipose tissue macrophages in the development of obesity-induced inflammation, insulin resistance and type 2 Diabetes

  2013influential reference
• Variant of TREM2 associated with the risk of Alzheimer's disease.

  2013cited by this paper
• Immunologic Privilege in the Central Nervous System and the Blood–Brain Barrier

  2013cited by this paper
• Intracranial Injection of Gammagard, a Human IVIg, Modulates the Inflammatory Response of the Brain and Lowers Aβ in APP/PS1 Mice Along a Different Time Course than Anti-Aβ Antibodies

  2013cited by this paper
• Immunosenescent CD8+ T Cells and C-X-C Chemokine Receptor Type 3 Chemokines Are Increased in Human Hypertension

  2013cited by this paper
• Cerebrospinal Fluid Biomarkers in Clinical Subtypes of Early-Onset Alzheimer's Disease

  2013cited by this paper
• TREM2 variants in Alzheimer's disease.

  2013cited by this paper
• Immune Regulation in T1D and T2D: Prospective Role of Foxp3+ Treg Cells in Disease Pathogenesis and Treatment

  2013influential reference
• Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?

  2013cited by this paper
• Microglial TNF-α-Dependent Elevation of MHC Class I Expression on Brain Endothelium Induced by Amyloid-Beta Promotes T Cell Transendothelial Migration

  2013cited by this paper
• Immunogenicity, Efficacy, Safety, and Mechanism of Action of Epitope Vaccine (Lu AF20513) for Alzheimer's Disease: Prelude to a Clinical Trial

  2013cited by this paper
• Brain Bioavailability of Human Intravenous Immunoglobulin and its Transport through the Murine Blood–Brain Barrier

  2013cited by this paper
• CXCL1 Contributes to β-Amyloid-Induced Transendothelial Migration of Monocytes in Alzheimer’s Disease

  2013cited by this paper
• Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers.

  2013cited by this paper
• The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy

  2013cited by this paper
• The therapeutics of Alzheimer's disease: Where we stand and where we are heading

  2013cited by this paper
• Microglia actions in Alzheimer’s disease

  2013cited by this paper
• The genetics of Alzheimer disease.

  2012cited by this paper
• Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study.

  2012cited by this paper
• Amyloid-related imaging abnormalities (ARIA) in Alzheimer’sdisease patients treated with bapineuzumab: A retrospective analysis

  2012cited by this paper
• Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.

  2012cited by this paper
• Short amyloid-&bgr; immunogens with spacer-enhanced immunogenicity without junctional epitopes for Alzheimer’s disease immunotherapy

  2012cited by this paper
• Animal models of Alzheimer disease.

  2012cited by this paper
• Targeting Beta Amyloid: A Clinical Review of Immunotherapeutic Approaches in Alzheimer's Disease

  2012cited by this paper
• Use it or lose it: establishment and persistence of T cell memory

  2012cited by this paper
• Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease.

  2012cited by this paper
• The genetics and neuropathology of Alzheimer’s disease

  2012cited by this paper
• Translational research in neurology: dementia.

  2012cited by this paper
• Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis

  2012cited by this paper
• Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature.

  2012cited by this paper
• Tau phosphorylation in human brain: relationship to behavioral disturbance in dementia.

  2012cited by this paper
• Systemic and Central Immunity in Alzheimer's Disease: Therapeutic Implications

  2012cited by this paper
• Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

  2012cited by this paper
• Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer’s disease

  2012cited by this paper
• The immune system in the aging human

  2012cited by this paper
• Apolipoprotein E4 Impairs Macrophage Efferocytosis and Potentiates Apoptosis by Accelerating Endoplasmic Reticulum Stress*

  2012cited by this paper
• The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update

  2012cited by this paper
• Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo‐controlled clinical trial

  2012cited by this paper
• The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment.

  2012influential reference
• Does vascular pathology contribute to Alzheimer changes?

  2012influential reference
• Chronological Age Impacts Immunotherapy and Monocyte Uptake Independent of Amyloid Load

  2012cited by this paper
• Immune profiling of Alzheimer patients.

  2012influential reference
• O4‐06‐02: Effects of human intravenous immunoglobulins on amyloid pathology and inflammation in a mouse model of Alzheimer's disease

  2011cited by this paper
• Neuroinflammation in Alzheimer's disease wanes with age

  2011cited by this paper
• Role of ninjurin‐1 in the migration of myeloid cells to central nervous system inflammatory lesions

  2011influential reference
• A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo

  2011cited by this paper
• A multimeric immunogen for the induction of immune memory to beta‐amyloid

  2011cited by this paper
• Review: Sporadic cerebral amyloid angiopathy

  2011cited by this paper
• Extended results of the Alzheimer's disease anti‐inflammatory prevention trial

  2011cited by this paper
• Omega-3 polyunsaturated fatty acids in Alzheimer's disease: key questions and partial answers.

  2011influential reference
• The ageing systemic milieu negatively regulates neurogenesis and cognitive function

  2011cited by this paper
• The role of G protein-coupled receptors in the pathology of Alzheimer's disease

  2011cited by this paper

• Health-Behavior Link: The Impact of Health Shocks on Asset Allocation and Consumption in Older Households

  2025cites this paper
• Mechanistic Approach to Immunity and Immunotherapy of Alzheimer's Disease: A Review.

  2024cites this paper
• Immunotherapy in Alzheimer's disease: focusing on the efficacy of gantenerumab on amyloid-β clearance and cognitive decline.

  2024cites this paper
• Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists in inflammatory diseases and cancers.

  2023cites this paper
• Recent Trends in Active and Passive Immunotherapies of Alzheimer’s Disease

  2023cites this paper
• Transcriptomics Meta-Analysis Reveals Phagosome and Innate Immune System Dysfunction as Potential Mechanisms in the Cortex of Alzheimer’s Disease Mouse Strains

  2023cites this paper
• Anti-Amyloid-β Immunotherapy: A Leading Novel Avenue for Alzheimer's Disease.

  2022cites this paper
• Immune-mediated diseases are associated with a higher incidence of dementia: a prospective cohort study of 375,894 individuals

  2022cites this paper
• Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases

  2021cites this paper
• Soluble Amyloid-β Consumption in Alzheimer’s Disease

  2021cites this paper
• Clinically approved IVIg delivered to the hippocampus with focused ultrasound promotes neurogenesis in a model of Alzheimer's disease.

  2020cites this paper
• Tetrahydrobiopterin Improves Recognition Memory in the Triple-Transgenic Mouse Model of Alzheimer’s Disease, Without Altering Amyloid-β and Tau Pathologies

  2020cites this paper
• Antibody-based therapies for Huntington's disease: current status and future directions.

  2019cites this paper
• Alzheimer’s disease-associated (hydroxy)methylomic changes in the brain and blood

  2019cites this paper
• Peripheral adaptive immunity of the triple transgenic mouse model of Alzheimer’s disease

  2019cites this paper
• Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimer’s disease pathogenesis

  2019cites this paper
• Functional autoantibodies in patients with different forms of dementia

  2018cites this paper
• The Contribution of Spleen Tyrosine Kinase to the Pathobiology of Alzheimer’s Disease

  2018influential citation
• Effets de l’administration de tétrahydrobioptérine en condition physiologique et pathologique : De la neurobiologie au comportement

  2018cites this paper
• An early diagnosis is not the same as a timely diagnosis of Parkinson's disease

  2018cites this paper
• Aging and Alzheimer’s disease: Comparison and associations from molecular to system level

  2018cites this paper
• TTC7 and Hyccin Regulate Neuronal Aβ42 Accumulation and its Associated Neural Deficits in Aβ42-Expressing Drosophila

  2018cites this paper
• Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches.

  2018cites this paper
• Losing connections in Alzheimer disease : the amyloid precursor protein processing machinery at the synapse

  2018cites this paper
• Pathogenic Feed-Forward Mechanisms in Alzheimer’s and Parkinson’s Disease Converge on GSK-3

  2018cites this paper
• Serum levels of proteins involved in amyloid-β clearance are related to cognitive decline and neuroimaging changes in mild cognitive impairment

  2018cites this paper
• Omega-3 polyunsaturated fatty acids and brain health: Preclinical evidence for the prevention of neurodegenerative diseases

  2017cites this paper
• Lessons from Anti-Amyloid-β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target

  2017cites this paper
• Novelties in the field of autoimmunity - 1st Saint Petersburg congress of autoimmunity, the bridge between east and west.

  2017cites this paper
• Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases

  2017cites this paper
• Alzheimer’s disease pathological lesions activate the spleen tyrosine kinase

  2017cites this paper
• Adeno-Associated Virus (AAV) as a Vector for Gene Therapy

  2017cites this paper
• Genetics of Parkinson’s disease and related disorders

  2017cites this paper
• Role of the CXCL 8-CXCR 1 / 2 Axis in Cancer and Inflammatory Diseases

  2017cites this paper
• Downregulation of RBO-PI4KIIIα Facilitates Aβ42 Secretion and Ameliorates Neural Deficits in Aβ42-Expressing Drosophila

  2017cites this paper